Sanofi to Invest More than $700 million into New Canadian Vaccine Manufacturing Facility

BioPharm International Editors

Set to be operational in 2026, the new facility will provide added antigen and filling capacity for Sanofi’s influenza vaccine, increasing its availability in Canada, the United States, and Europe.

Sanofi announced on March 31, 2021 that it has invested more than €600 million (US$704 million) into a new vaccine manufacturing facility at its existing site in Toronto, Canada.

Set to be operational in 2026, the new facility will provide added antigen and filling capacity for Sanofi’s Fluzone High-Dose Quadrivalent influenza vaccine, increasing its availability in Canada, the United States, and Europe, Sanofi said in a company press release.

“As a leading vaccines Company, we continuously look ahead to address the fast-growing demand for those influenza vaccines that have demonstrated clinical superiority against standard-dose vaccines. Fluzone High-Dose provides a long-term competitive advantage, and this new investment will ensure more seniors around the world are better protected against influenza and its complications. In addition, it will be a key resource to assist against future pandemics,” said Paul Hudson, CEO, Sanofi, in the press release. “We welcome the ongoing partnership with the Canadian authorities, who supported us to make today’s great news a reality; this will make the country, which has a strong legacy in vaccines research and development, one of our key hubs in our effort to protect and improve human health across the globe.”

Source: Sanofi